Daiichi Sankyo (OTCMKTS:DSNKY) Releases FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.910-0.910 for the period, compared to the consensus estimate of 1.040. The company issued revenue guidance of $14.5 billion-$14.5 billion, compared to the consensus revenue estimate of $13.4 billion.

Daiichi Sankyo Stock Performance

Daiichi Sankyo stock opened at $17.05 on Tuesday. The company’s 50-day moving average price is $17.84 and its 200-day moving average price is $20.32. Daiichi Sankyo has a twelve month low of $15.56 and a twelve month high of $28.21. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. The company has a market cap of $32.30 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 0.85 and a beta of -0.25.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its earnings results on Monday, May 11th. The company reported $0.15 earnings per share for the quarter. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities research analysts forecast that Daiichi Sankyo will post 1.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.